This site is intended for healthcare professionals

Sumitomo Biopharma acquires control of Urovant and with it vibegron a proposed treatment for overactive bladder

Read time: 1 mins
Last updated:15th Nov 2020
Published:15th Nov 2020
Type: industry
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest